Trademark Information

Application ID
Status
Date of Application
20 June 2017
Classes
5
Proprietor
Brinton House, Survey No.55/2, Kharadi , Pune – 411 014
Attorney
Vishesh And Associates[10756]
301/302, A Wing, 3 Rd Floor, Shaheen Chambers, Dawood Baug, Opp. Pearl Heritage, Andheri (West), Mumbai 400 058.
Type
Device
State
Maharashtra
Country
Filing Mode
e-Filing
IP Office
MUMBAI
Used Since
Valid / Upto
Description
[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements

Image (DEVICE)

Defdef Device mark 3575131 Trademark

Documents

Examination Report

Uploaded Documents

1 TM-A(TRADE MARKS APPLICATION) 20 Jun 2017
2 Reply to Exam Report (MIS-R) 01 Aug 2017
3 TM-M(EXTENSION OF TIME) 15 Apr 2019
4 Authorization Letter 09 Jul 2019
5 Authorization Letter 24 Sep 2019

Correspondence and Notices

1 Hearing Notice (Show Cause) 7875781 3921009 28 Feb 2019
2 Hearing notice (Adjourned) 8380366 4199186 06 Jun 2019
3 Hearing notice (Adjourned) 8760018 4384684 13 Aug 2019
4 Hearing notice (Adjourned) 9099409 4530370 16 Oct 2019
5 Tribunal Refused Notice for : 3575131 9408677 4618750 14 Dec 2019

Frequently Asked Questions

When was the trademark applied?

The application for Defdef was made on 20 June 2017.

Who is the applicant for Defdef?

The trademark applicant for Defdef is BRINTON PHARMACEUTICALS.

In what class is the trademark applied to?

Defdef is applied in class(es) 5.

What is the status of the trademark application?

Application for Defdef is on Refused stage.

What is the application ID of the trademark?

Application Id allotted to Defdef is 3575131.

Who is the trademark agent or attorney?

Trademark agent or attorney for the application is Vishesh And Associates.

What is the type of trademark application?

Defdef filed with the Intellectual property office as a DEVICE.